Development and validation of RP-HPLC method for simultaneous determination of metformin hydrochloride, Empagliflozin, and Pitavastatin
Acta Chromatographica · 03.06.2026
DOI: 10.1556/1326.2026.01469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Chromatographica, erschienen am 03.06.2026. Verfasst von Hafiz Muhammad Umar Nisar und 7 weiteren Autor:innen. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
HPLC is an analytical method that provides precise, accurate, and simultaneous quantification of one or more drugs in the formulation, ensuring an accurate dose of active ingredients. The current research work focuses on developing and validating a reversed-phase high-performance liquid chromatography (RP-HPLC) procedure that can quantify three drugs, i.e., Empagliflozin, Pitavastatin, and Metformin HCl, simultaneously. The validation of the developed method was performed as per the Q2 (R1) guidelines of the International Council for Harmonization (ICH). The analytical procedure was performed on a Shimadzu HPLC system, having an Agilent C18 column (250 mm × 4.6 mm, 5 μm). The chromatography method used an isocratic mobile phase comprising a solution A having pH 3.5 ± 0.05 (consisting of KH 2 PO 4 solution with the ion-pairing agent i.e., sodium 1-heptanesulfonate), and acetonitrile mixed in a 55:45 V/V ratio, pumped at a flow speed of 1.20 mL min −1 . Wavelength was set at 260 nm (3.4 min) and 220 nm (12 min) to detect the peaks of the drugs at column oven temperature maintained at 25 °C. The method was characterized by determining and evaluating different values, including linearity, precision, robustness, system suitability, solution stability, and specificity. The approximate retention time for Metformin HCl was 2.0 min, for Empagliflozin was 4.1 min, and for Pitavastatin was 8.5 min. The results of the research showed that all three drugs were effectively distinguished with excellent resolution. The value of linearity was determined by using concentrations ranging between 5 and 7.5 μg mL −1 for Empagliflozin, 0.4–0.6 μg mL −1 for Pitavastatin, and 100–150 μg mL −1 for Metformin HCl. The values of R 2 were 0.9999, 0.9999, and 0.9991, for Pitavastatin, Empagliflozin, and Metformin HCl, respectively. The method was proven to be accurate, with recovery values of 99.70–100.08% for Pitavastatin, 100.55–101.23% for Empagliflozin, and 98.15–101.76% for Metformin HCl. The results of the study demonstrated that the developed procedure was linear, precise, rapid, accurate, robust, and found to be applicable for the simultaneous determination of Metformin HCl, Pitavastatin, and Empagliflozin.
Zitieren
APA
Nisar, H. M. U., Siddique, W., Zaman, M., Shamshair, M. Z., Alkholifi, F. K., Qadri, M., Alquraini, A., & Khan, A. (2026). Development and validation of RP-HPLC method for simultaneous determination of metformin hydrochloride, Empagliflozin, and Pitavastatin. Acta Chromatographica. https://doi.org/10.1556/1326.2026.01469
Vancouver
Nisar HMU, Siddique W, Zaman M, Shamshair MZ, Alkholifi FK, Qadri M, et al. Development and validation of RP-HPLC method for simultaneous determination of metformin hydrochloride, Empagliflozin, and Pitavastatin. Acta Chromatographica. 2026. doi:10.1556/1326.2026.01469
BibTeX
@article{Nisar2026,
author = {Nisar, Hafiz Muhammad Umar and Siddique, Waqar and Zaman, Muhammad and Shamshair, Muhammad Zeeshan and Alkholifi, Faisal K and Qadri, Marwa and Alquraini, Ali and Khan, Abida},
title = {Development and validation of RP-HPLC method for simultaneous determination of metformin hydrochloride, Empagliflozin, and Pitavastatin},
journal = {Acta Chromatographica},
year = {2026},
doi = {10.1556/1326.2026.01469}
}
EUVIMED